Tectonic Therapeutic, Inc.

TECXSEC EDGAR

Biological Products, (No Diagnostic Substances)(NY)CIK: 1681087

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$41.4M	$37.0M	$72.2M	$83.1M	$87.2M
Operating Expenses	$58.0M	$44.6M	$105.4M	$118.8M	$120.2M
Operating Income (Loss)	-$58.0M	-$44.6M	-$105.4M	-$118.8M	-$120.2M
Nonoperating Income (Expense)	$33.0K	$1.8M	-$456.0K	-$285.0K	$516.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$58.0M	—	—	—	—
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	—	—
Net Income (Loss) Attributable to Parent	-$58.0M	-$42.8M	-$105.9M	-$119.1M	-$119.7M
Earnings Per Share, Basic	-$6.83	-$33.76	-$2.42	-$2.78	—
Earnings Per Share, Diluted	-$6.83	-$33.76	-$2.42	-$2.78	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$152.9M	$39.4M	$103.9M	$203.8M	$271.2M
Assets, Current	$146.9M	$30.9M	$100.0M	$199.1M	$267.2M
Cash and Cash Equivalents, at Carrying Value	$141.2M	$28.8M	$92.6M	$189.6M	$259.7M
Liabilities	$12.1M	$43.4M	$28.6M	$34.4M	$16.9M
Liabilities, Current	$11.6M	$40.9M	$13.1M	$19.4M	$16.6M
Long-term Debt	—	—	—	$15.0M	$15.0M
Accounts Payable, Current	$976.0K	$409.0K	$384.0K	$3.5M	$2.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$59.1M	-$40.7M	-$97.2M	-$98.0M	-$98.8M
Net Cash Provided by (Used in) Investing Activities	-$156.0K	-$279.0K	-$267.0K	-$2.5M	-$1.2M
Net Cash Provided by (Used in) Financing Activities	$171.7M	$33.7M	$262.0K	$30.4M	$172.6M
Payments to Acquire Property, Plant, and Equipment	$156.0K	$279.0K	$267.0K	$2.5M	$1.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)